EMA: Insufficient data linking GSK vax with narcolepsy; Greece cuts more brands from formulary;

@FiercePharma: Generics makers need to change their spots--and learn marketing--to sell biosimilars, Actavis CEO says. More | Follow @FiercePharma

> European regulators wrapped up a safety review of GlaxoSmithKline's ($GSK) flu shot Pandemrix, saying evidence linking it with narcolepsy is "insufficient." Report

> Greece dropped plans to claw back pharma industry revenues to make up for overspending on outpatient drug therapy, but apparently cut some branded drugs from its new formulary. Report

> U.S. officials confirmed that a deadly fungus implicated in a meningitis outbreak was present in one lot of steroids supplied by New England Compounding Center. Report

> The FDA plans to allow Sun Pharmaceuticals to continue importing its version of the Johnson & Johnson ($JNJ) cancer drug Doxil until the branded product shortage completely resolves. Report

> AstraZeneca ($AZN) won a £5 million investment from a U.K. government fund to back its efforts toward a potential BioScience cluster at its R&D facility in Alderley Park. Report

Medical Device News

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Complete Genomics scores patent win over Illumina. Story

> Study: To reduce heart disease risks, gastric banding beats drugs. News

> Sony slashes jobs on road to medical device focus. Item

Biotech News

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Novo's long-acting insulin degludec takes big step to megamarket status. Story

> Wanted: Premier hepatitis C drug developer to partner with Vertex. News

> U.K.'s Redx blueprints big R&D spinoff funded by government grant. Article

And Finally... Blood hormone tests predicted a woman's risk for developing postmenopausal breast cancer for up to 20 years, a new study found. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.